Wikidata entity: Q220426
C₁₇H₁₇ClN₆O₃ (P274)
Quantities
| P4250 | defined daily dose | 7.5 |
| P2067 | mass | 388.105066 |
| P233 | canonical SMILES | String | CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl | ??? |
| P373 | Commons category | String | Zopiclone | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2175 | medical condition treated | ... | Q177190 (sleep disorder) | sleep disorder |
| P129 | physically interacts with | ... | Q5512777 (Gamma-aminobutyric acid type A receptor subunit alpha4) | Gamma-aminobutyric acid type A receptor subunit alpha4 |
| P129 | physically interacts with | ... | Q21113312 (Gamma-aminobutyric acid type A receptor subunit beta3) | Gamma-aminobutyric acid type A receptor subunit beta3 |
| P129 | physically interacts with | ... | Q21113314 (Gamma-aminobutyric acid type A receptor subunit beta2) | Gamma-aminobutyric acid type A receptor subunit beta2 |
| P129 | physically interacts with | ... | Q21114574 (Gamma-aminobutyric acid type A receptor subunit beta1) | Gamma-aminobutyric acid type A receptor subunit beta1 |
| P129 | physically interacts with | ... | Q21114578 (Gamma-aminobutyric acid type A receptor subunit alpha3) | Gamma-aminobutyric acid type A receptor subunit alpha3 |
| P3489 | pregnancy category | ... | Q3679261 (Australian pregnancy category C) | Australian pregnancy category C |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P769 | significant drug interaction | ... | Q55434 (pethidine) | pethidine |
| P769 | significant drug interaction | ... | Q58614 (loxapine) | loxapine |
| P769 | significant drug interaction | ... | Q81225 (morphine) | morphine |
| P769 | significant drug interaction | ... | Q174723 (codeine) | codeine |
| P769 | significant drug interaction | ... | Q176533 (alfentanil) | alfentanil |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q407535 (oxycodone) | oxycodone |
| P769 | significant drug interaction | ... | Q407541 (fentanyl) | fentanyl |
| P769 | significant drug interaction | ... | Q407592 (tramadol) | tramadol |
| P769 | significant drug interaction | ... | Q303646 (hydromorphone) | hydromorphone |
| P769 | significant drug interaction | ... | Q377270 (dihydrocodeine) | dihydrocodeine |
| P769 | significant drug interaction | ... | Q407721 (buprenorphine) | buprenorphine |
| P769 | significant drug interaction | ... | Q414463 (tapentadol) | tapentadol |
| P769 | significant drug interaction | ... | Q417915 (sufentanil) | sufentanil |
| P769 | significant drug interaction | ... | Q2622907 (periciazine) | periciazine |
| P769 | significant drug interaction | ... | Q7553347 (sodium oxybate) | sodium oxybate |
| P279 | subclass of | ... | Q11173 (chemical compound) | chemical compound |
| P2868 | subject has role | ... | Q50377192 (hypnotics and sedatives) | hypnotics and sedatives |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | zopiclone | ??? |
Why not click here or view trends?
log id: 2090577